Zhonghua Xue Ye Xue Za Zhi. 2025 Mar 14;46(3):198-208. doi: 10.3760/cma.j.cn121090-20241122-00469.
Monoclonal gammopathy of undetermined significance (MGUS) is the most common type of plasma cell disorder, characterized by clonal proliferation of plasma cells in the bone marrow, a mild increase in monoclonal protein (M protein), and no organ damage. Smoldering multiple myeloma (SMM) is a plasma cell disease that lies between MGUS and active multiple myeloma (AMM), featuring elevated levels of M protein in the plasma and increased plasma cell infiltration in the bone marrow, but without typical clinical manifestations. SMM is considered as a precursor state to AMM. This consensus was jointly developed by the Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association and the Chinese Myeloma Committee-Chinese Hematology Association, covering the epidemiological characteristics, clinical manifestations, testing and examination, diagnostic criteria, differential diagnosis, prognosis assessment, and patient management strategies for MGUS and SMM. The consensus aims to provide standardized guidance for the comprehensive management of MGUS and SMM, ensuring timely monitoring of disease progression and intervention at the appropriate time to improve the quality of life and survival rates of patients.
意义未明的单克隆丙种球蛋白病（MGUS）是最常见的浆细胞疾病类型，其特征为骨髓中浆细胞的克隆性增殖、单克隆蛋白（M蛋白）轻度升高且无器官损害。冒烟型多发性骨髓瘤（SMM）是一种介于MGUS和活动性多发性骨髓瘤（AMM）之间的浆细胞疾病，其特点是血浆中M蛋白水平升高以及骨髓中浆细胞浸润增加，但无典型临床表现。SMM被认为是AMM的前驱状态。本共识由中华医学会血液学分会浆细胞疾病学组、中国医师协会血液科医师分会骨髓瘤专业委员会共同制定，涵盖MGUS和SMM的流行病学特征、临床表现、检验检查、诊断标准、鉴别诊断、预后评估及患者管理策略。该共识旨在为MGUS和SMM的综合管理提供标准化指导，确保及时监测疾病进展并在适当时候进行干预，以提高患者的生活质量和生存率。
